Literature DB >> 22895519

The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient.

Jai Radhakrishnan1, Daniel C Cattran.   

Abstract

The KDIGO guideline for glomerulonephritis is designed to assist health-care providers in treating patients with glomerular diseases. A guideline is not a set of rules but is intended to allow the practitioner to make an informed decision based on the available evidence. Due to its general nature and the variability of strength of the available studies, it is often difficult to directly apply a guideline to the care of an individual patient. This commonly relates to the limited generalizability of the evidence, i.e., does not cover every clinical scenario. To underscore this point, we have introduced within the context of the glomerulonephritis guideline cases with specific features to illustrate the constant need for clinical judgment. These vignettes are intended to demonstrate how the best treatment plans should be individualized and take into account patient preference and clinical acumen, as well as the best available evidence.

Entities:  

Mesh:

Year:  2012        PMID: 22895519     DOI: 10.1038/ki.2012.280

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  134 in total

1.  Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

2.  Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.

Authors:  Yusuke Okabayashi; Nobuo Tsuboi; Kotaro Haruhara; Go Kanzaki; Kentaro Koike; Akihiro Shimizu; Yoichi Miyazaki; Iwao Ohno; Tetsuya Kawamura; Makoto Ogura; Takashi Yokoo
Journal:  Clin Exp Nephrol       Date:  2016-02-01       Impact factor: 2.801

3.  American Society of Nephrology quiz and questionnaire 2014: glomerular diseases.

Authors:  Andrew S Bomback; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-09       Impact factor: 8.237

4.  A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome.

Authors:  Martina Soldarini; Lucia Farina; Augusto Genderini; Niccolo Bolli
Journal:  BMJ Case Rep       Date:  2017-07-14

5.  Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.

Authors:  Michael A Paley; Fahad Edrees; Satoru Kudose; Joseph P Gaut; Prabha Ranganathan; Anitha Vijayan
Journal:  Saudi J Kidney Dis Transpl       Date:  2019 Jan-Feb

Review 6.  Glomerular diseases: FSGS.

Authors:  Bhadran Bose; Daniel Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

7.  Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible.

Authors:  Ilka Klaassen; Bünyamin Özgören; Carolin E Sadowski; Kristina Möller; Michael van Husen; Anja Lehnhardt; Kirsten Timmermann; Folke Freudenberg; Udo Helmchen; Jun Oh; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

Review 8.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

9.  IgA Nephritis with Declining Renal Function: Treatment with Corticosteroids May Be Worthwhile.

Authors:  Claudio Ponticelli; Richard J Glassock
Journal:  J Am Soc Nephrol       Date:  2015-02-12       Impact factor: 10.121

10.  The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Authors:  Marie C Hogan; Heather N Reich; Peter J Nelson; Sharon G Adler; Daniel C Cattran; Gerald B Appel; Debbie S Gipson; Matthias Kretzler; Jonathan P Troost; John C Lieske
Journal:  Kidney Int       Date:  2016-08-12       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.